XNK 04
Alternative Names: XNK-04Latest Information Update: 11 Oct 2023
At a glance
- Originator XNK Therapeutics
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Liver cancer
Most Recent Events
- 11 Oct 2023 Preclinical trials in Liver cancer in Sweden (Parenteral) (XNK Therapeutics pipeline, October 2023)
- 04 May 2023 XNK Therapeutics plans a preclinical study in Liver cancer
- 04 May 2023 XNK Therapeutics enters into research agreement with unknown company for preclinical trial of XNK 04 in Liver cancer